sr 33557 has been researched along with desipramine in 4 studies
Studies (sr 33557) | Trials (sr 33557) | Recent Studies (post-2010) (sr 33557) | Studies (desipramine) | Trials (desipramine) | Recent Studies (post-2010) (desipramine) |
---|---|---|---|---|---|
50 | 3 | 1 | 5,775 | 487 | 414 |
Protein | Taxonomy | sr 33557 (IC50) | desipramine (IC50) |
---|---|---|---|
Solute carrier family 22 member 1 | Homo sapiens (human) | 9.18 | |
5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.35 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0003 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.35 | |
Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0034 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0003 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0003 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.35 | |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.0031 | |
Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 7.8 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.35 | |
5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.35 | |
5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.35 | |
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.35 | |
5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | 0.35 | |
Histamine H1 receptor | Rattus norvegicus (Norway rat) | 0.0008 | |
Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.1961 | |
5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | 0.35 | |
5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | 0.35 | |
5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | 0.35 | |
5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 0.35 | |
Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0003 | |
Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | 3.8 | |
Sodium-dependent dopamine transporter | Homo sapiens (human) | 9.9 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.4035 | |
Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 1.52 | |
5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 0.35 | |
5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 0.35 | |
Solute carrier family 22 member 2 | Rattus norvegicus (Norway rat) | 10 | |
Transporter | Rattus norvegicus (Norway rat) | 7.8 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (50.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
Bordier, C; Chen, KG; Durán, GE; Jaffrézou, JP; Laurent, G; Levade, T; Muller, C; Sikic, BI | 1 |
Lee, JY; Leonhardt, LG; Obeid, LM | 1 |
Hata, R; Kato, Y; Kubota, E; Miyazaki, K; Ozawa, S; St-Pierre, Y; Tsukuda, M | 1 |
4 other study(ies) available for sr 33557 and desipramine
Article | Year |
---|---|
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance.
Topics: Affinity Labels; Animals; Desipramine; Doxorubicin; Drug Interactions; Drug Resistance, Multiple; Indolizines; Leukemia P388; Lysosomes; Mianserin; Mice; Phenethylamines; Rhodamine 123; Rhodamines; Sphingomyelin Phosphodiesterase; Trimipramine; Tumor Cells, Cultured; Vasodilator Agents; Vinblastine | 1995 |
Cell-cycle-dependent changes in ceramide levels preceding retinoblastoma protein dephosphorylation in G2/M.
Topics: Carboxylic Acids; Cell Cycle; Cell Line; Ceramides; Desipramine; Enzyme Inhibitors; Fibroblasts; Fumonisins; G2 Phase; Humans; Indolizines; Kinetics; Mitosis; Nocodazole; Oxidoreductases; Phenethylamines; Phosphorylation; Retinoblastoma Protein; Sphingomyelin Phosphodiesterase; Thymidine | 1998 |
Acidic extracellular pH increases calcium influx-triggered phospholipase D activity along with acidic sphingomyelinase activation to induce matrix metalloproteinase-9 expression in mouse metastatic melanoma.
Topics: Animals; Calcium; Calcium Channel Blockers; Calcium Channels; Cell Line, Tumor; Chelating Agents; Desipramine; Egtazic Acid; Enzyme Activation; Extracellular Fluid; Hydrogen-Ion Concentration; Indolizines; MAP Kinase Signaling System; Matrix Metalloproteinase 9; Melanoma; Mibefradil; Mice; NF-kappa B; Nimodipine; Perhexiline; Phenethylamines; Phospholipase D; Phosphorylation; Promoter Regions, Genetic; Sphingomyelin Phosphodiesterase | 2007 |